Evidence map›Paper›PMID 42050327›Full record

ArticleGenes and immunity2026

Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.

Samera H Hamad, Chelsea Katz, Helen Toma, Kosuke Murakami, Nasrine Bendjilali, Gord Zhu, Hadi Shojaei, Lanlan Fang, Samuel Leung, Martin Koebel and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genes and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Samera H HamadDepartment of Surgery, Cooper Medical School of Rowan University, Camden, NJ, USA. samera3h@gmail.com.ORCID http://orcid.org/0000-0003-4997-3324
Chelsea Katz *Cooper University Health Care, Camden, NJ, USA.
Helen Toma *Cooper University Health Care, Camden, NJ, USA.
Kosuke MurakamiDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID http://orcid.org/0000-0003-4278-5849
Nasrine BendjilaliCollege of Science and Mathematics, Rowan University, Glassboro, NJ, USA.
Gord ZhuMD Anderson Cancer Center at Cooper, Camden, NJ, USA.
Hadi ShojaeiMD Anderson Cancer Center at Cooper, Camden, NJ, USA.
Lanlan FangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Samuel LeungDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Martin KoebelDepartment of Pathology, University of Calgary, Calgary, AB, Canada.
Huseyin KaradumanNorth Carolina State University, Raleigh, NC, USA.
Oliver AbinaderDivision of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Ramkrishna MitraDivision of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Lauren KrillMD Anderson Cancer Center at Cooper, Camden, NJ, USA.
Christina ChuMD Anderson Cancer Center at Cooper, Camden, NJ, USA.
David P WarshalMD Anderson Cancer Center at Cooper, Camden, NJ, USA.
Yemin WangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NRF2 modulates tumor immune microenvironment in several cancers. NRF2 is activated in about 50% of high-grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. Through analyzing data from scRNA-seq (n = 7), bulk RNA-seq (n = 365), and tumor microarray (TMA) of human HGSOC (n = 240) samples, we demonstrated that NRF2 expression correlated with tumor immune microenvironment in HGSOC. Functional pathway enrichment analysis and transcription factors (TFs) prediction showed the functional relevance of NRF2 expression in shaping the immune phenotype of HGSOC. Pathways such as hedgehog and ROS signaling, and TFs including EGR1, ESRRA, SMAD proteins, and SP-family proteins, are implicated in the immune suppressive microenvironment of NRF2

Indexed as

Cystadenocarcinoma, SerousNF-E2-Related Factor 2Ovarian NeoplasmsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, TumorNFE2L2 protein, humanNF-E2-Related Factor 2

Identifiers

PMID42050327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.